Physician profile
Benjamin Kuritzky
NPI 1063730323
$5,728.90
in general payments reported to CMS, 2019-2025
50 companies · $1,121 in 2025
The $1,121 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.31 · 2020: $37.70 · 2021: $126 · 2022: $634 · 2023: $2,469 · 2024: $1,282 · 2025: $1,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,166 · Consulting Fee: $1,665 · Education: $41.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,165.68 |
| Consulting Fee | $1,665.00 |
| Education | $41.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,848.15 | 2023-2025 | Calquence, Imfinzi, Enhertu |
| Novartis Pharmaceuticals Corporation | $349.67 | 2019-2025 | |
| Pfizer INC. | $305.10 | 2021-2025 | |
| Celgene Corporation | $210.21 | 2022-2025 | Reblozyl, Pomalyst |
| Merck Sharp & Dohme LLC | $177.76 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Pharmacyclics LLC, An Abbvie Company | $172.07 | 2021-2023 | Imbruvica |
| Lilly USA, LLC | $164.53 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Genzyme Corporation | $162.57 | 2022-2025 | |
| Seagen INC. | $162.41 | 2022-2023 | Padcev, Tukysa |
| Emd Serono, INC. | $142.34 | 2024 | |
| Daiichi Sankyo INC. | $135.53 | 2020-2025 | Enhertu, Injectafer |
| Amgen INC. | $131.63 | 2019-2023 | Lumakras |
| Incyte Corporation | $122.26 | 2021-2024 | Jakafi, Monjuvi, Pemazyre |
| Aveo Pharmaceuticals, INC. | $121.13 | 2023-2025 | Fotivda |
| Array Biopharma INC | $117.33 | 2022-2025 | Lorbrena, Braftovi, Mektovi |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $89.80 | 2023-2025 | Padcev, Xospata |
| Abbvie INC. | $89.14 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $78.77 | 2021-2024 | Libtayo |
| Gilead Sciences, INC. | $70.29 | 2021-2024 | Trodelvy |
| Kite Pharma, INC. | $69.41 | 2024-2025 | Yescarta |
| Taiho Oncology, INC. | $68.47 | 2023-2025 | |
| Genentech USA, INC. | $67.62 | 2023-2025 | Polivy, Venclexta, Tecentriq Hybreza |
| Ipsen Biopharmaceuticals, INC | $63.98 | 2019-2025 | Onivyde |
| Mirati Therapeutics, INC. | $62.54 | 2023-2024 | Krazati |
| Sun Pharmaceutical Industries INC. | $58.30 | 2023-2024 | Yonsa, Odomzo |
| Rigel Pharmaceuticals, INC. | $51.87 | 2023-2025 | Rezlidhia, Gavreto, Tavalisse |
| Boston Scientific Corporation | $51.35 | 2021-2024 | Watchman Flx |
| Alexion Pharmaceuticals, INC. | $46.24 | 2024-2025 | Ultomiris |
| Janssen Biotech, INC. | $45.45 | 2025 | Tecvayli, Darzalex, Talvey |
| Adaptive Biotechnologies Corporation | $39.51 | 2023-2025 | Clonoseq |
| Stemline Therapeutics INC. | $37.30 | 2023-2024 | Orserdu |
| Agios Pharmaceuticals, INC. | $35.30 | 2024-2025 | Pyrukynd |
| Therapeuticsmd, INC. | $33.98 | 2022 | |
| Immunocore Limited | $33.97 | 2024 | Kimmtrak |
| E.R. Squibb & Sons, L.L.C. | $30.98 | 2022-2024 | |
| Pharmaessentia USA Corporation | $29.17 | 2025 | Besremi |
| Exelixis INC. | $27.61 | 2025 | Cabometyx |
| Eisai INC. | $24.27 | 2023 | |
| Beone Medicines USA, INC. | $23.92 | 2025 | Tevimbra |
| Cumberland Pharmaceuticals, INC. | $22.83 | 2024 | Sancuso |
| Tersera Therapeutics LLC | $21.16 | 2023 | Zoladex |
| Jazz Pharmaceuticals INC. | $19.92 | 2024 | |
| Apellis Pharmaceuticals, INC. | $19.18 | 2023 | Empaveli |
| Bayer Healthcare Pharmaceuticals INC. | $16.97 | 2024 | |
| Sumitomo Pharma America, INC. | $16.83 | 2023 | Orgovyx |
| Janssen Pharmaceuticals, INC | $15.96 | 2024 | Xarelto |
| Deciphera Pharmaceuticals INC. | $15.64 | 2023 | Qinlock |
| Kyowa Kirin, INC. | $14.79 | 2023 | Poteligeo |
| Cti Biopharma Corp. | $13.69 | 2023 | Vonjo |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Kuritzky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.